# Atrasentan in Treating Patients With Prostate Cancer

> **NCT00046943** · PHASE3 · COMPLETED · sponsor: **Abbott**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** atrasentan hydrochloride

## Key facts

- **NCT ID:** NCT00046943
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046943, "Atrasentan in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00046943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*